www.dermatologiepropraxi.cz / Dermatol. praxi. 2024;18(2):97-104 / DERMATOLOGIE PRO PRAXI 103 PŘEHLEDOVÉ ČLÁNKY Farmakologická léčba hyperpigmentace LITERATURA 1. Fitzpatrick TB, Breathnach AS. The Epidermal Melanin Unit Systém. Dermatol Wochenschr. 1963;147:481-489. 2. Slominski A, Tobin DJ, Shibahara S, et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:11551228. 3. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 2007;445:843-850. 4. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. 1995 Nov;11(3):328-30. doi: 10.1038/ng1195-328. 5. Robbins LS, Nadeau JH, Johnson KR, et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell. 1993;72:827-834. 6. Rana BK, Hewett-Emmett D, Jin L, et al. High polymorphism at the human melanocortin 1 receptor locus. Genetics. 1999;151:1547-1557. 7. D’Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV- -induced tanning. Nature. 2006;443:340-344. 8. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128:853-864. 9. Bertolotto C, Abbe P, Hemesath TJ, et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol. 1998;148:827-835. 10. Price ER, Horstmann MA, Wells AG, et al. Alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol Chem. 1998;273:33042-33047. 11. Esposito ACC, Brianezi G, de Souza NP, et al. Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study. Int J Cosmet Sci. 2018;40:420-424. 12. Im S, Kim J, On WY, et al. Increased expression of alpha- -melanocyte-stimulating hormone in the lesional skin of melasma. Br J Dermatol. 2002;146:165-167. 13. Miot LD, Miot HA, Polettini J, et al. Morphologic changes and the expression of alpha-melanocyte stimulating hormone and melanocortin-1 receptor in melasma lesions: a comparative study. Am J Dermatopathol. 2010;32:676-682. 14. Ortonne JP, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc. 2008;13:10-14. 15. Park JY, Park JH, Kim SJ, et al. Two histopathological patterns of postinflammatory hyperpigmentation: epidermal and dermal. J Cutan Pathol. 2017;44:118-124. 16. Baranska A, Shawket A, Jouve M, et al. Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal. J Exp Med. 2018;215:1115-1133. 17. Weiss JS, James WD, Cooper KD. Melanophages in inflammatory skin disease demonstrate the surface phenotype of OKM5+ antigen-presenting cells and activated macrophages. J Am Acad Dermatol. 1988;19:633-641. 18. Weismann K, Lorentzen HF. Dermoscopic color perspective. Arch Dermatol. 2006;142:1250. 19. Praetorius C, Sturm RA, Steingrimsson E. Sun-induced freckling: ephelides and solar lentigines. Pigment Cell Melanoma Res. 2014;27:339-350. 20. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol. 1979;73:141-143. 21. Wester RC, Melendres J, Hui X, et al. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J Toxicol Environ Health A. 1998;54:301-317. 22. Kerscher M, Buntrock H. Topische Behandlung von Pigmentstörungen mit kosmetischen und pharmazeutischen Wirkstoffen [Topical treatment of pigmentation disorders with cosmetic and pharmaceutical agents]. Hautarzt. 2020 Dec;71(12):944-949. German. doi: 10.1007/s00105-020-047198. PMID: 33146766. 23. Palumbo A, d’Ischia M, Misuraca G, et al. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991;1073:85-90. 24. Sakuma K, Ogawa M, Sugibayashi K, et al. Relationship between tyrosinase inhibitory action and oxidation-reduction potential of cosmetic whitening ingredients and phenol derivatives. Arch Pharm Res. 1999;22:335-339. 25. Stratford MR, Ramsden CA, Riley PA. The influence of hydroquinone on tyrosinase kinetics. Bioorg Med Chem. 2012;20:4364-4370. 26. Smith CJ, O’Hare KB, Allen JC. Selective cytotoxicity of hydroquinone for melanocyte-derived cells is mediated by tyrosinase activity but independent of melanin content. Pigment Cell Res. 1988;1:386-389. 27. Jimbow K, Obata H, Pathak MA, et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436449. 28. Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048-1065. 29. Hsieh PW, Al-Suwayeh SA, Fang CL,et al. The co-drug of conjugated hydroquinone and azelaic acid to enhance topical skin targeting and decrease penetration through the skin. Eur J Pharm Biopharm. 2012;81:369-378. 30. Hsieh PW, Aljuffali IA, Fang CL, et al. Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs. J Dermatol Sci. 2014;76:120-131. 31. Hsieh PW, Chen WY, Aljuffali IA, et al. Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid. Curr Med Chem. 2013;20:4080-4092. 32. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996;276:765-769. 33. Chawla S, deLong MA, Visscher MO, et al. Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. Br J Dermatol. 2008;159:1267-1274. 34. Nakajima M, Shinoda I, Fukuwatari Y, et al. Arbutin increases the pigmentation of cultured human melanocytes through mechanisms other than the induction of tyrosinase activity. Pigment Cell Res. 1998 Feb;11(1):12-7. doi: 10.1111/j.16000749.1998.tb00705.x. PMID: 9523330. 35. Schallreuter KU, Wood JW. A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res.1990;282:168-171. 36. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies.Cutis.1996;57:36-45. 37. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58-61. 38. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895. 39. Yun CY, Mi Ko S, Pyo Choi Y, et al. Alpha-Viniferin Improves Facial Hyperpigmentation via Accelerating Feedback Termination of cAMP/PKA-Signaled Phosphorylation Circuit in Facultative Melanogenesis. Theranostics. 2018;8:2031-2043. 40. Lee KT, Kim BJ, Kim JH, et al. Biological screening of 100 plant extracts for cosmetic use (I): inhibitory activities of tyrosinase and DOPA auto-oxidation. Int J Cosmet Sci. 1997;19:291-298. 41. Jo H, Choi M, Sim J, et al. Synthesis and biological evaluation of caffeic acid derivatives as potent inhibitors of alpha- -MSH-stimulated melanogenesis. Bioorg Med Chem Lett. 2017;27:3374-3377. 42. Yun CY, Hong SD, Lee YH, et al. Nuclear Entry of CRTC1 as Druggable Target of Acquired Pigmentary Disorder. Theranostics. 2019;9:646-660. 43. Del Rosario E, Florez-Pollack S, Zapata L Jr., et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78:363-369. 44. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75:385-392. 45. Lajevardi V, Ghayoumi A, Abedini R, et al. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up. J Cosmet Dermatol. 2017;16:235-242. 46. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392. 47. Battaini G, Monzani E, Casella L, et al. Inhibition of the catecholase activity of biomimetic dinuclear copper complexes by kojic acid. J Biol Inorg Chem. 2000;5:262-268. 48. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282-284. 49. Ellis CN, Weiss JS, Hamilton TA, et al. Sustained improvement with prolonged topical tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol. 1990;23:629-637. 50. Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753-757. 51. Weinstein GD, Nigra TP, Pochi PE, et al. Topical tretinoin for treatment of photodamaged skin. A multicenter study. Arch Dermatol. 1991;127:659-665. 52. Nguyen NT, Fisher DE. MITF and UV responses in skin: From pigmentation to addiction. Pigment Cell Melanoma Res. 2019;32:224-236. 53. Vachiramon V, Kositkuljorn C, Leerunyakul K, et al. Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation. J. Cosmet. Dermatol. 2021;20:987-992. doi: 10.1111/jocd.13615. 54. Lima P, Dias J, Cassiano D, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: An evaluator-blinded, randomized controlled trial. J. Eur. Acad. Dermatol. Venereol. 2021;35:1881-1887. doi: 10.1111/jdv.17344.] 55. Arrowitz C, Schoelermann AM, Mann T, et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J. Investig. Dermatol. 2019;139:1691-1698.e6. doi: 10.1016/j.jid.2019. 02. 013. 56. Roggenkamp D, Sammain A, Fürstenau M, et al. Thiamidol ® in moderate-to-severe melasma: 24-week, randomized, double-blind, vehicle-controlled clinical study with subsequent regression phase. J. Dermatol. 2021;48:1871-1876. doi: 10.1111/1346-8138.16080. 57. Sarkar R, Garg V, Chugh S. Newer and upcoming therapies for melasma. Indian J. Dermatol. Venereol. Leprol. 2012;78:417428. doi: 10.4103/0378-6323.98071. 58. Yousefi A, Khoozani ZK, Forooshani SZ, et al. Is Topical Zinc Effective in the Treatment of Melasma? A Double-Blind Randomized Comparative Study. Dermatol. Surg. 2014;40:3337. doi: 10.1111/dsu.12296. 59. Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: What is available? J. Cutan. Aesthetic Surg. 2013;6:4–11. doi: 10.4103/0974-2077.110089. 60. Hwang SW, Oh DJ, Lee D, et al. Clinical Efficacy of 25% l-Ascorbic Acid (C’ensil) in the Treatment of Melasma. J. Cutan. Med. Surg. 2009;13:74-81. doi: 10.2310/7750.2008.07092. 61. Breathnach AC, Nazzaro-Porro M, Passi S, Zina G. Azelaic acid therapy in disorders of pigmentation. Clin Dermatol. 1989 Apr-Jun;7(2):106-19. doi: 10.1016/0738-081x(89)900618. PMID: 2667735. 62. Song M, Mun JH, Ko HC, et al. Korean Red Ginseng Powder in the Treatment of Melasma: An Uncontrolled Observational Study. J. Ginseng Res. 2011;35:170-175. doi: 10.5142/ jgr.2011. 35. 2.170.
RkJQdWJsaXNoZXIy NDA4Mjc=